The Evolving Treatment Landscape of Advanced Renal Cell Carcinoma in Patients Progressing after VEGF Inhibition

Despite significant changes in the therapeutic landscape of renal cell carcinoma, the majority of patients with metastatic disease eventually progress after first-line treatment with vascular endothelial growth factor receptors (VEGFR) tyrosine kinase inhibitor (TKI) therapy. Understanding existing...

Descripción completa

Detalles Bibliográficos
Autores principales: Barata, Pedro C., Ornstein, Moshe C., Garcia, Jorge A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Codon Publications 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5515898/
https://www.ncbi.nlm.nih.gov/pubmed/28725539
http://dx.doi.org/10.15586/jkcvhl.2017.69
Descripción
Sumario:Despite significant changes in the therapeutic landscape of renal cell carcinoma, the majority of patients with metastatic disease eventually progress after first-line treatment with vascular endothelial growth factor receptors (VEGFR) tyrosine kinase inhibitor (TKI) therapy. Understanding existing data on subsequent therapies is crucial to define an optimal treatment sequence following first-line failure. This review examines the data supporting currently approved agents in this setting and provides a framework for decision-making regarding treatment sequencing beyond first-line therapy with VEGFR TKIs.

Ejemplares similares